The new assay is meant to be used in conjunction with a full clinical and laboratory assessment.
Low-dose vaginal softgel is approved for treating moderate to severe dyspareunia associated with menopause.
More than one-quarter of women with a hip fracture will be dead within 12 months; maintaining and protecting bone health postmenopause is...
Low-dose testosterone treatment may be considered for HSDD in carefully selected menopausal women after standard therapies have been tried but...
Women in midlife with the most stress had the most benefit from mindfulness.
Brought to you by Radius Health, Inc.
Dr. Richard-Davis served as the Scientific Program Chair of the 2018 NAMS Meeting. In this audiocast she highlights several clinical takeaways...
Age and previous hormone replacement therapy did not influence prasterone’s efficacy in treating dyspareunia.
What works best for genitourinary syndrome of menopause: vaginal estrogen, vaginal laser, or combined laser and estrogen therapy?
There are not enough data to recommend laser therapy over the gold standard, transvaginal estrogen, for treating symptoms of the...
From the Journals
Vitamin D supplementation does not appear to reduce the risk of falls or fracture or to improve bone mineral density.
Coverage and expert comment on new insights on HT and Alzheimer disease risk, HT route and sexuality outcomes, mortality in WHI participants, and...
Women with osteopenia who received intravenous zoledronate had a significantly lower risk of fractures.